US › Healthcare

Nephros Inc (NEPH)

US · Healthcare · Medical Instruments & Supplies

$3.65+3.99%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$6.0M

Revenue YoY

+36.2%

Net profit

$1.2M

Profit YoY

+405.1%

EPS

$0.06

EPS estimate

$0.01

Net margin

19.9%

EPS came in at 0.06 against a street estimate of 0.01 — a beat of 500.0%.

Key statistics

Market cap

$39.0M

P/E

23.9

Forward P/E

0.0

P/B

3.82

Book value

$1.10

EPS (TTM)

$0.15

52-week high

$6.42

52-week low

$2.66

50-day MA

$4.10

200-day MA

$3.76

Beta

1.64

Analyst view

Analysts rate Nephros Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $6.25.

Shareholding

Insiders

18.74%

Institutions

17.84%

Largest institutional holders

Fund	Stake
Wexford Capital LP	33.15%
Topline Capital Management LLC	4.93%
Vanguard Capital Management, LLC	1.83%
Morgan Stanley - Brokerage Accounts	1.19%
Petersen Flynn & Dinsmore Inc	1.19%
Bard Associates Inc	1.09%
Renaissance Technologies Corp	0.71%
Geode Capital Management, LLC	0.65%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nephros Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.